Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
MS-553 in relapsed or refractory B-cell lymphoma
CTR20223051Phase 2Terminated
- Sponsor
- Mingsairuilin Pharmaceutical
- Start
- Nov 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of MS-553 in B-cell non-Hodgkin lymphoma (B-NHL), mantle cell lymphoma (MCL), malignant B-cell neoplasm, sponsored by Mingsairuilin Pharmaceutical. Started Nov 2022; status: terminated.
02
Drugs
MS-553
03
Conditions
B-cell non-Hodgkin lymphoma (B-NHL)mantle cell lymphoma (MCL)malignant B-cell neoplasm
Beyond the preview
Go deeper on CTR20223051.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20223051.